Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 12/20 | 0.52 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20481975 | 0.91 | SCN9A (0.53) | SCN9ASCN5AFYNCDK8CDK19 | |
| SCHEMBL18096744 | 0.82 | SCN9A (0.58) | SCN9ASCN5AESR1 | |
| SCHEMBL18096619 | 0.82 | SCN9A (0.61) | SCN9ASCN5ANPC1FYN | |
| SCHEMBL9181218 | 0.81 | SCN9A (0.48) | SCN9ASCN5A | |
| SCHEMBL18096640 | 0.78 | SCN9A (0.55) | SCN9ASCN5ANPC1FYNIDO1 | |
| SCHEMBL20481837 | 0.78 | SCN9A (0.66) | SCN9ASCN5ACDK8CDK19 | |
| SCHEMBL18096753 | 0.77 | SCN9A (0.80) | SCN9ASCN5A | |
| SCHEMBL20481944 | 0.77 | SCN9A (0.49) | SCN9ASCN5ANPC1FYNESR1 | |
| SCHEMBL20481830 | 0.76 | SCN9A (0.48) | SCN9ASCN5ACDK8CDK19ESR1 | |
| Trifluoroacetic Acid SCHEMBL15093797 | 0.76 | SCN9A (0.48) | SCN9ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10173985-B2 | Aminoindazole derivatives as sodium channel inhibitors | ALMIRALL, S.A. (ES) | 2019-01-08 | — | — | US | disclosed |
| US-20180244626-A1 | AMINOINDAZOLE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | ALMIRALL, S.A. (ES) | 2018-08-30 | — | — | US | disclosed |
| EP-3274335-A1 | AMINOINDAZOLE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | Almirall S.A. (ES) | 2018-01-31 | — | — | EP | disclosed |
| WO-2016150971-A1 | AMINOINDAZOLE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | ALMIRALL, S.A. (ES) | 2016-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180244626-A1 | AMINOINDAZOLE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | SCN1B, SCN1A, SCN3A | SCN9A 31/4885SCN5A 4/4885NPC1 539/4885 |
| US-10173985-B2 | Aminoindazole derivatives as sodium channel inhibitors | SCN1B, SCN1A, SCN3A | SCN9A 29/4885SCN5A 4/4885NPC1 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.